Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

Lucy Batizovsky | April 2, 2026 | Appointment | |  Faron Pharmaceuticals 

Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, has appointed Heikki Jouttijärvi as Chief Technical Officer (CTO).

Jouttijärvi brings decades of experience to the role, having most recently been the Senior Vice President (SVP) of Commercial Business Operations at Adverum Biotechnologies.

He has also previously held multiple global roles at Menlo Therapeutics and Santen Pharmaceutical Company.

Advertisement

Juho Jalkanen, CEO of Faron, said: “Heikki’s wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced Phase IIb trial in HR MDS.”

Heikki Jouttijärvi, newly appointed CTO of Faron Pharmaceuticals, said: “I have been amazed by the resilience and excellent hard work done with bexmarilimab to date. We look forward to advancing the programme to the benefit of patients.”

Related Content

drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline …

pentagon-headquarters-us-department-of-defense-virginia

US Department of Defense selects Faron for $6.1m COVID-19 research funding

The US Department of Defense (DoD) has selected Faron Pharmaceuticals’ HIBISCUS study to receive $6.1 …

Pharma manufacturing news in brief

Another J&J recall in the US, plus a round-up of product recalls, acquisitions, facility updates …

The Gateway to Local Adoption Series

Latest content